Story
Forte Biosciences Stock Soars on $2.2 Billion Acquisition by Argenx
Summary
Shares of the clinical-stage biotech surged nearly 40% after argenx announced a definitive agreement to acquire the company for $77 per share in an all-cash deal valued at approximately $2.2 billion.
Shares of Forte Biosciences (FBRX) surged nearly 40% in pre-market trading on July 27, 2026, after the company agreed to be acquired by argenx in an all-cash transaction. The deal values the clinical-stage biotechnology firm at an equity value of approximately $2.2 billion.
The Acquisition Terms
Under the terms of the definitive agreement, argenx will launch a tender offer to acquire all outstanding shares of Forte Biosciences for $77.00 per share in cash. According to the announcement, this price represents a significant premium for Forte shareholders:
- A premium of approximately 40% to Forte's last closing price.
- An 86% premium to the stock's volume-weighted average price since the company reported positive clinical data on July 9, 2026.
The transaction, which was unanimously approved by the boards of directors of both companies, is expected to close in the third quarter of 2026. Argenx plans to fund the acquisition entirely from its existing cash reserves.
Strategic Focus on Autoimmune Pipeline
AdThe acquisition is centered on Forte's lead drug candidate, FB102, a first-in-class anti-CD122 antibody. The asset has attracted significant interest following positive Phase 1b study results showing statistically significant efficacy in treating both vitiligo and celiac disease.
Forte's pipeline addresses two autoimmune conditions with substantial unmet medical needs and a lack of currently approved biologic treatments. This deal aligns with a broader industry trend of larger pharmaceutical and biotech companies acquiring smaller firms with promising, de-risked assets to bolster their own development pipelines.
Market Context and Investor Confidence
Forte's stock price climbed to trade just below the announced acquisition price, signaling strong investor confidence that the transaction will be completed. The deal follows a recent signal of growing institutional conviction in Forte's potential, when Barclays initiated coverage with an Overweight rating and a $74 price target just days before the acquisition was announced.
Read next
More on Stocks
White House Blocks CNN from Air Force One Press Pool, Washington Post Reports
The White House has reportedly denied CNN a spot on Air Force One for President Donald Trump's upcoming trip to Tennessee, according to The Washington Post. The move marks a significant development in the administration's contentious relationship with the news network.
Morgan Stanley Public Finance Co-Head Zach Solomon Departs for TD Securities
Zach Solomon, co-head of public finance investment banking at Morgan Stanley, has joined TD Securities amid the Canadian bank's expansion in the U.S. municipal bond market. The move follows the recent Chapter 11 bankruptcy filing of a key client, Brightline.
OpenAI Models Accessed Public Data From SEC, Census Bureau Websites, Bloomberg Reports
OpenAI's AI models reportedly interacted with publicly available data on U.S. government websites, including the SEC and Census Bureau, prompting the company to launch a review of the activity.
Citigroup Targets Over $3 Billion Banamex IPO for January, Bloomberg Reports
Citigroup is reportedly preparing for an initial public offering of its Mexican retail unit, Banamex, that could raise over $3 billion and is targeted for January. The move represents a major step in the bank's multi-year strategy to exit international consumer banking operations.